HORSHAM, Penn., Nov. 13, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") $(SSKN)$, a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended September 30, 2025, and provides a corporate update.

Third Quarter Highlights

   -- Continued progress toward historic expansion of CPT codes for 
      reimbursement for inflammatory and auto-immune skin diseases, effectively 
      tripling the covered patient population in the US, including recent 
      recognition of expanded CPT codes by the Center for Medicare and Medicaid 
      Services $(CMS)$ 2026 final PFS (Physician Fee Schedule) rule 
 
   -- COFEPRIS (Mexican regulatory agency) clearance of TheraClearX in Mexico 
      and first commercial placements 
 
   -- Multiple new peer-reviewed publications further validating the XTRAC$(R)$ 
      gold standard clinical outcomes in treatment of autoimmune diseases -- in 
      vitiligo in combination therapy with JAK inhibitors, in psoriasis in 
      combination therapy with topical drug, as breakthrough therapy for 
      localized atopic dermatitis, and in treating mycosis fungiodes (a rare 
      variant of cutaneous lymphoma). The Company holds patents for these 
      combination treatments, further positioning XTRAC as the only clinically 
      proven and intellectual property protected solution 
 
   -- Positive developments in the ongoing lawsuit against LaserOptek with the 
      addition of LaserOptek Korea and C. Dalton, LLC as defendants, improving 
      the opportunity for collecting damages 
 
   -- Recapturing of dozens of partner clinics previously lost to LaserOptek 
      under false representation of ability to claim insurance reimbursement 
      with anything but Excimer Laser 
 
   -- Average gross billings per device of $5,981 increased 8.5% over the 
      comparable prior-year period, and represents the highest gross billings 
      per device per quarter since the fourth quarter of 2022 
 
   -- U.S. install base of XTRAC devices declined by 6 during the third quarter 
      of 2025, to 838 
 
   -- US install base of TheraClearX of 161 
 
   -- Gross margin for the quarter came in at 60%, roughly in line with third 
      quarter 2024 
 
   -- EBITDA was slightly positive in the third quarter of 2025 vs. negative 
      $0.2 million in the comparable prior-year period 
 
   -- Total revenue declined by $1.9 million due to softness in international 
      markets driven primarily by instability in international trade policy 
 
   -- Ended the second quarter of 2025 with $7.1 million of cash following $2.4 
      million registered direct offering 

"We continue to see solid recurring revenue expansion in partner clinics with meaningful growth in "same store sales". We are further excited for the potential in growth in the coming quarters based on anticipation of the newly approved reimbursement codes in new indications for our XTRAC Excimer laser treatment. Recent acknowledgement of these codes by the Centers for Medicare and Medicaid Services are helping to expand interest from patients and practitioners alike in the expanded potential for new treatments and additional revenue streams, respectively. XTRAC has become the established gold standard in narrow band UVB treatment for skin disorders, and we continue to refine our business, as well as provide important resources for our clinician partners, that we believe will continue to yield positive results and growth. In the meantime, positive outcomes in our ongoing litigation have brought new customers to the fold, which we anticipate will ultimately translate to increased revenue over the coming quarters. In the meantime, as always, we continue to carefully manage costs and strategically expand our patient pool through our DTC efforts, while strengthening our practice partners through our consulting services," stated Dr. Dolev Rafaeli, STRATA President and Chief Executive Officer.

Third Quarter 2025 Financial Results

Revenue for the third quarter of 2025 was $6.9 million, a decrease of 21% vs. the third quarter of 2024. Global recurring revenue of $5.5 million increased 3% YoY and equipment revenue of $1.4 million decreased 60% in the third quarter of 2025 compared with the prior year third quarter.

Gross profit for the third quarter of 2025 was $4.2 million, or 60% of revenue, down from $5.3 million in the third quarter of 2024.

Total operating expenses were $5.4 million in the third quarter of 2025 vs. $6.9 million in the prior-year period.

Net loss for the third quarter of 2025 was $1.6 million, or EPS of negative $0.36 per basic and diluted common share, as compared to a net loss of $2.1 million, or EPS of negative $0.51 per basic and diluted common share, in the third quarter of 2024.

Cash and cash equivalents at September 30, 2025 were $7.1 million.

Third Quarter 2025 Earnings Conference Call

STRATA management will host a conference call at 4:30 p.m. ET on Thursday, November 13, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session.

To listen to the conference call, interested parties within the U.S. should dial 1-866-524-3160 (domestic) or 1-412-317-6760 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the STRATA Skin Sciences, Inc. conference call.

The conference call will also be available through a live webcast that can be accessed at STRATA Skin Sciences Q3 2025 Earnings Webcast.

A telephonic replay of the call will be available until November 20, 2025 by dialing 1-855-669-9658 (or 1-412-317-0088 for international toll callers) and using replay access code 3125911. To access the replay using an international dial-in number, please see here.

A webcast earnings call replay will be available approximately one hour after the live call and remain accessible until May 13, 2026.

Non-GAAP Financial Measures

STRATA has determined to supplement its consolidated financial statements, prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"), presented elsewhere within this report, with certain non-GAAP measures of financial performance. These non-GAAP measures include non-GAAP gross profit, which excludes the non-cash expense of amortization of acquired intangible assets classified as cost of revenues, and non-GAAP adjusted EBITDA, "Earnings Before Interest, Taxes, Depreciation, and Amortization."

These non-GAAP disclosures have limitations as an analytical tool, should not be viewed as a substitute for Gross Profit or Net Earnings (Loss) determined in accordance with U.S. GAAP, should not be considered in isolation or as a substitute for analysis of our results as reported under U.S. GAAP, nor are they necessarily comparable to non-GAAP performance measures that may be presented by other companies. STRATA considers these non-GAAP measures in addition to its results prepared under current accounting standards, but they are not a substitute for, nor superior to, U.S. GAAP measures. These non-GAAP measures are provided to enhance readers' overall understanding of STRATA's current financial performance and to provide further information for comparative purposes. This supplemental presentation should not be construed as an inference that the Company's future results will be unaffected by similar adjustments to Gross Profit or Net Earnings (Loss) determined in accordance with U.S. GAAP. Specifically, STRATA believes the non-GAAP measures provide useful information to management and investors by isolating certain expenses, gains, and losses that may not be indicative of the Company's core operating results and business outlook. In addition, STRATA believes non-GAAP measures enhance the comparability of results against prior periods.

Reconciliation to the most directly comparable U.S. GAAP measure of all non-GAAP measures included in this press release is as follows:

 
                  Three Months Ended     Nine Months Ended 
                     September 30,         September 30, 
                 ---------------------  -------------------- 
(in thousands)     2025      2024         2025      2024 
                  ------    ------       ------    ------ 
Net loss         $(1,622)  $(2,074)     $(6,319)  $(5,531) 
 
Adjustments: 
  Depreciation 
   and 
   amortization      864     1,239        3,302     3,738 
  Amortization 
   of operating 
   lease 
   right-of-use 
   asset              87        81          259       255 
  Loss on 
   disposal of 
   property and 
   equipment          20        19           83        38 
  Interest 
   expense, 
   net               449       469        1,131     1,425 
                  ------    ------       ------    ------ 
Non-GAAP EBITDA     (202)     (266)      (1,544)      (75) 
  Employee 
   retention 
   credit              -         -            -      (864) 
  Stock-based 
   compensation      212        26          469       301 
  Inventory 
   write-off           -         -            -       141 
                  ------    ------       ------    ------ 
Non-GAAP 
 adjusted 
 EBITDA          $    10   $  (240)     $(1,075)  $  (497) 
                  ======    ======       ======    ====== 
 
 

XTRAC Gross Domestic Recurring Billings

XTRAC gross domestic recurring billings represent the amount invoiced to partner clinics when treatment codes are sold to the physician. It does not include normal GAAP adjustments, which are deferred revenue from prior quarters recorded as revenue in the current quarter, the deferral of revenue from the current quarter recorded as revenue in future quarters, adjustments for co-pay and other discounts. This excludes international recurring revenues.

(MORE TO FOLLOW) Dow Jones Newswires

November 13, 2025 16:05 ET (21:05 GMT)